Rnav8 BIO
Laguna Niguel, US · Founded 2022 · Delaware corporation · 6 employees on LinkedIn · 4 known investors
RNAV8 Bio develops a toolkit for engineering mRNA therapeutics, optimizing non-coding sequences to improve expression and efficacy of mRNA-based treatments. The company serves pharmaceutical and biotech organizations seeking to expand the clinical application of mRNA technology.
Founders & leadership
Rnav8 BIO was founded in 2022 by Devan Shah and Michelle Lynn Hall.
DS
Devan Shah
ML
Michelle Lynn Hall
Investors · 4
Reported raises · per SEC filings
Form D private placements$2M disclosed across 1 round · 2022
▶$2MraisedMar 2025 · 42 investors · BiotechnologyRule 506(b)
▶$2MraisedMar 2025 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Devan ShahExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $2M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Rnav8 BIO do?
- RNAV8 Bio develops a toolkit for engineering mRNA therapeutics, optimizing non-coding sequences to improve expression and efficacy of mRNA-based treatments. The company serves pharmaceutical and biotech organizations seeking to expand the clinical application of mRNA technology.
- Who founded Rnav8 BIO?
- Rnav8 BIO was founded by Devan Shah, Michelle Lynn Hall in 2022.
- Who are Rnav8 BIO's investors?
- Rnav8 BIO's investors include BioBrit, Elmehøj Ventures, Portal Innovations, Service Provider Capital.
- How much funding has Rnav8 BIO raised?
- Rnav8 BIO has disclosed $2M raised across 1 round.
- Where is Rnav8 BIO headquartered?
- Rnav8 BIO is headquartered in Laguna Niguel, US.